Two Studies Support Short Dual Antiplatelet Therapy With Abbott’s Xience DES
Executive Summary
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
You may also be interested in...
FDA Approves Medtronic’s Resolute Onyx DES With Short-Term Dual-Antiplatelet Therapy
The agency approved Medtronic's zotarolimus-eluting coronary stent for patients with a high bleeding risk who are treated with one month of dual-antiplatelet therapy.
FDA Approves Boston Scientific’s SYNERGY BP Stent For High Bleeding Risk Patients
The bioabsorbable polymer-coated, sirolimus-eluting stent is the first drug-eluting stent approved for this population.
Varian Launches Trial Of Flash Ultra-High Dose Radiotherapy
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: